Boundless Bio, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.84M | 4.74M | 4.19M | 4.48M | 4.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.76M | 14.48M | 14.00M | 15.15M | 17.06M |
| Operating Income | -22.76M | -14.48M | -14.00M | -15.15M | -17.06M |
| Income Before Tax | -23.69M | -13.56M | -12.89M | -13.88M | -15.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.69M | -13.56M | -12.89M | -13.88M | -15.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.69M | -13.56M | -12.89M | -13.88M | -15.68M |
| EBIT | -22.76M | -14.48M | -14.00M | -15.15M | -17.06M |
| EBITDA | -21.50M | -14.19M | -13.70M | -14.84M | -16.74M |
| EPS Basic | -1.06 | -0.60 | -0.58 | -0.62 | -0.70 |
| Normalized Basic EPS | -0.61 | -0.38 | -0.36 | -0.39 | -0.44 |
| EPS Diluted | -1.06 | -0.60 | -0.58 | -0.62 | -0.70 |
| Normalized Diluted EPS | -0.61 | -0.38 | -0.36 | -0.39 | -0.44 |
| Average Basic Shares Outstanding | 22.45M | 22.41M | 22.40M | 22.39M | 22.36M |
| Average Diluted Shares Outstanding | 22.45M | 22.41M | 22.40M | 22.39M | 22.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |